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Abstract
Objective—Magnetic resonance spectroscopy (MRS) is a non-invasive method to quantify 
neurometabolite concentrations in the brain. Within the framework of the WELDOX II study, we 
investigated the association of exposure to manganese (Mn) and iron (Fe) with γ-aminobutyric 
acid (GABA) and other neurometabolites in the striatum and thalamus of 154 men.
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Material and methods—GABA-edited and short echo-time MRS at 3T was used to assess 
brain levels of GABA, glutamate, total creatine (tCr) and other neurometabolites. Volumes of 
interest (VOIs) were placed into the striatum and thalamus of both hemispheres of 47 active 
welders, 20 former welders, 36 men with Parkinson’s disease (PD), 12 men with hemochromatosis 
(HC), and 39 male controls. Linear mixed models were used to estimate the influence of Mn and 
Fe exposure on neurometabolites while simultaneously adjusting for cerebrospinal fluid (CSF) 
content, age and other factors. Exposure to Mn and Fe was assessed by study group, blood 
concentrations, relaxation rates R1 and R2* in the globus pallidus (GP), and airborne exposure 
(active welders only).
Results—The median shift exposure to respirable Mn and Fe in active welders was 23 μg/m3 and 
110 μg/m3, respectively. Airborne exposure was not associated with any other neurometabolite 
concentration. Mn in blood and serum ferritin were highest in active and former welders. GABA 
concentrations were not associated with any measure of exposure to Mn or Fe. In comparison to 
controls, tCr in these VOIs was lower in welders and patients with PD or HC. Serum 
concentrations of ferritin and Fe were associated with N-acetylaspartate, but in opposed directions. 
Higher R1 values in the GP correlated with lower neurometabolite concentrations, in particular tCr 
(exp(β)=0.87, p<0.01) and choline (exp(β)=0.84, p=0.04). R2* was positively associated with 
glutamate-glutamine and negatively with myo-inositol.
Conclusions—Our results do not provide evidence that striatal and thalamic GABA differ 
between Mn-exposed workers, PD or HC patients, and controls. This may be due to the low 
exposure levels of the Mn-exposed workers and the challenges to detect small changes in GABA. 
Whereas Mn in blood was not associated with any neurometabolite content in these VOIs, a higher 
metal accumulation in the GP assessed with R1 correlated with generally lower neurometabolite 
concentrations.
Keywords
Welders; Globus pallidus; Magnetic resonance spectroscopy; Glutamate; Parkinson; 
Haemochromatosis
1. Introduction
Manganese (Mn) is an essential trace element naturally found in the environment. It is 
required for a variety of key physiological processes (Chen et al., 2015). Commonly, 
sufficient amounts of Mn are supplied by the diet; however, occupational settings, such as 
Mn mining (Myers et al., 2003), steel and alloy production (Bouchard et al., 2008) or 
welding (Ellingsen et al., 2014; Long et al., 2014a; Pesch et al., 2012) present increased 
risks for systemic exposure and brain accumulation of this metal (Fitsanakis et al., 2006). In 
addition to Mn, iron (Fe) is a major constituent of welding fume (Flynn and Susi, 2010; 
Pesch et al., 2012). Both metals share biological transport systems due to their structural 
similarity, partly indicated by a negative association of Mn in blood (MnB) and serum 
ferritin (SF) (Aguirre and Culotta, 2012). Mn accumulates in brain regions susceptible to 
oxidative stress, preferentially in the globus pallidus (GP) (Bowman and Aschner, 2014). Fe 
accumulates preferentially in the substantia nigra (SN), where Fe, dopamine and 
neuromelanin are linked to the etiology brain aging and Parkinson’s disease (PD) (Jiang et 
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al., 2016; Zucca et al., 2015). Several studies visualized Mn and Fe accumulation in the 
brain by using increased T1-weighted/R1 and T2*-weighted/R2* signals in magnetic 
resonance imaging (MRI) (Lee et al., 2015; Lee et al., 2016; Long et al., 2014a).
Various neurological dysfunctions have been recognized ranging from subclinical 
neurobehavioral effects associated with low Mn exposure to manganism as a 
neurodegenerative disease following high exposure (Iannilli et al., 2016; Mergler et al., 
1999; Racette et al., 2017; Zoni and Lucchini, 2013). Brain metabolites have been proposed 
as markers for an early detection of Mn neurotoxicity before structural damage can be 
ascertained (Zheng et al., 2011). Furthermore, changes in brain Fe status have been shown to 
modify neurometabolite homeostasis (Kim and Wessling-Resnick, 2014). Within the 
framework of the WELDOX II study, magnetic resonance spectroscopy (MRS) was used to 
quantify neurometabolites for an investigation of the effects of airborne or systemic Mn and 
Fe on brain metabolism in the striatum and thalamus. MRS allows estimating the content of 
neurometabolites such as γ-aminobutyric acid (GABA; major inhibitory neurotransmitter), 
total creatine (tCr; involved in energy metabolism), N-acetylaspartate (NAA; a marker of 
general neuronal function), N-acetylaspartylglutamate (NAAG; most concentrated peptide in 
the brain), myo-inositol (mI; a glial cell marker), glutamate (Glu; an excitatory 
neurotransmitter), glutamine (Gln; precursor of Glu and GABA), and choline-containing 
compounds (Cho; an indicator of cell membrane integrity) in the selected brain regions 
(Dydak et al., 2011).
Several MRS studies have linked occupational exposure to Mn and Fe or PD to changes in 
neurometabolite concentrations (Dydak et al., 2016; Guilarte, 2013). Thalamic GABA was 
elevated in smelters (Dydak et al., 2011; Long et al., 2014b) and PD patients 
(Dharmadhikari et al., 2015). However, results on striatal GABA concentrations in PD are 
controversial (Dharmadhikari et al., 2015; Emir et al., 2012). Furthermore, thalamic mI was 
reduced in welders and smelters (Long et al., 2014a). Other neurometabolites (Cho and Glu) 
were not altered in various brain regions (Chang et al., 2009; Dydak et al., 2011; Kim et al., 
2007). Non-human primates exposed to Mn showed a significant decrease of NAA/Cr in the 
parietal cortex, but not in striatum, thalamus and frontal white matter, and no alterations 
were reported for other metabolites (Cho, mI) (Guilarte et al., 2006). In rodents, the main 
neurochemical effect was an increase in striatal GABA concentrations throughout a wide 
range of Mn exposures (Gwiazda et al., 2007).
The aim of this analysis within the framework of the WELDOX II study was to explore the 
association of diverse measures of exposure to Mn and Fe with the content of 
neurometabolites in volumes of interests (VOIs) placed in thalamus and striatum of both 
hemispheres. Considering prior reports on alterations in the GABAergic system, the 
hypokinetic nature of parkinsonism symptoms and the excitatory projection of the thalamus 
to cortical regions in the motor pathway, we hypothesized welders will show increased 
thalamic concentration of the inhibitory neurotransmitter GABA. Due to the importance of 
Glu in basal ganglia pathways and the fact that Glx is co-edited in GABA-edited spectra, 
and the reported changes in NAA and mI in Mn exposure (Chang et al., 2009; Dydak et al., 
2011; Guilarte et al., 2006; Kim et al., 2007), as well as the reported changes in tCr, Cho and 
mI in PD and neurodegenerative diseases in general (Dydak et al., 2016; Öz et al., 2014), all 
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these neurochemicals were included in our models. Metal exposure was assessed with a 
comparison of study groups being at-risk occupations (active and former welders), patients 
with PD or hemochromatosis (HC), and controls recruited from the general population. 
Furthermore, biomarkers in the blood and brain as well as airborne exposure in active 
welders were analyzed. To our knowledge, this is the first study to investigate the effect of 
both redox-active metals on the concentrations of GABA, NAA and other neurometabolites 
in the living human brain in such an extensive manner.
2. Material and methods
2.1 Study population
In total, 174 participants were recruited for the neuroimaging study WELDOX II from 2013 
to 2016. Eligible men were 45 years or older and did not meet any exclusion criterion 
(claustrophobia, metal fragments in the eyes, carrying a cardiac pacemaker or cochlear 
implant, large tattoos). For this analysis, participants were excluded if MRS data was 
completely missing, brain neoplasms or other pathologic changes were detected during MRI, 
Fe status and MnB were incomplete, or GABAergic medication was taken. Here, the study 
population comprised 154 men: 47 active welders, 20 former welders, 39 controls, 36 PD 
patients, and 12 HC patients).
Active welders were recruited from 14 companies located in different areas of North Rhine-
Westphalia. Twenty-one welders (45%) performed gas metal arc welding (GMAW) with 
solid or flux-cored wire. Most of the other welders performed tungsten inert gas welding 
(TIG). Personal exposure to respirable welding fume was measured in the breathing zone 
during a working shift. Post-shift blood samples were drawn for the determination of Mn. 
Neuroimaging and neurological examination of active welders was conducted about six 
weeks later in the study center.
Former welders and controls were recruited from the general population of the greater 
Bochum area. Controls were eligible if they had never worked as welder and did not suffer 
from diseases that may impair motor function. PD patients were enrolled from the 
department of neurology of the Sankt Joseph Hospital in Bochum. HC patients were 
recruited through their self-help organization.
All participants provided a blood sample for the determination of the blood count and 
laboratory diagnostics of Fe metabolism, including SF and serum Fe (SFe), gamma-glutamyl 
transferase (GGT) and other liver enzymes at the day of neuroimaging at the Institute of 
Clinical Chemistry, Transfusion and Laboratory Medicine of the Berufsgenossenschaftliches 
University Hospital Bergmannsheil with methods as formerly described for the WELDOX 
study (Casjens et al., 2014). GGT ≥ 56 U/L (90th percentile) was considered as indicative for 
a potential liver dysfunction. In addition, carbohydrate-deficient transferrin (CDT) was 
determined and values > 2.6% were used to indicate a risk for alcohol abuse.
Socio-demographic characteristics, occupational history, medications, and chronic diseases 
were assessed by questionnaire. A supplemental questionnaire for welders documented their 
welding history. All participants underwent a neurological assessment of movement 
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disorders by a neurologist (MDS UPDRS rating) and further examinations, e.g. fine motor 
test, odor identification, and balance tests.
All participants provided written informed consent. The study protocol was approved by the 
Ethics Committee of the Ruhr University Bochum, Germany.
2.2 Airborne exposure to Mn and Fe
Personal air sampling was performed in all active welders. The concentrations of respirable 
Mn and Fe were measured as previously described (Pesch et al., 2012). PGP-EA samplers 
were used for collecting respirable particles at a flow rate of 3.5 L/min in the breathing zone 
of the active welders (Lehnert et al., 2012). Sampling duration was four hours on average. 
Mn and Fe were determined by inductively coupled plasma mass spectrometry (ICP-MS) 
with a Perkin Elmer Elan DRC II (Waltham, Massachusetts). The samples were prepared 
according to a standard protocol (Hebisch et al.). For the statistical analyses, measurements 
below the limits of quantitation (LOQs) were converted to 0.5* LOQ (Mn: one measurement 
< LOQ, Fe: four measurements < LOQ). The German occupational exposure limit (OEL) for 
respirable Mn is 20 μg/m3 (https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-
Regeln/Regelwerk/TRGS/TRGS-900.html). No German OEL has been established for 
respirable Fe.
2.3 Determination of Mn in whole blood
MnB was determined at the Institute for Prevention and Occupational Medicine of the 
German Social Accident Insurance by means of inductively coupled plasma-quadrupole 
mass spectrometry (ICP-MS). Plastic materials were used for sample preparation to prevent 
metal contamination. Thawed blood samples (400 μL) were diluted 1:12.5 with a 0.5% 
solution of ammonium hydroxide and 100 μL of a 0.2% solution of Triton-X. Rhodium was 
used as internal standard. Analysis was carried out using a 7700 ICP-MS system from 
Agilent Technologies in He-mode (flow rate: 5 mL/min) with a collision cell to avoid 
interferences. Calibration and calculation of the Mn concentration were carried out using 
standards prepared in sheep blood at eight different concentrations. Materials from RECIPE 
(ClinChek Whole Blood Level, lyophil. for Trace Elements I and II, REF 8840, LOT 227) 
and SERONORM (Trace Elements Whole Blood Level I and II, LOT 1103129) served as 
internal control.
2.4 MRI and MRS data acquisition and processing
MRI scans were performed on a 3 T Philips Achieva X-series whole-body clinical scanner 
(Philips Healthcare, Best, The Netherlands) with a 32-channel head coil. R1 (1/T1) and R2* 
(1/T2*) relaxation rates were measured bilaterally in regions of interest (ROIs) placed in the 
GP, SN, and frontal lobe (FL). We performed the positioning in duplicate and used the 
arithmetic means of R1 respectively of R2* from both readers for the statistical analysis. T1-
weighted 3D turbo field echo images (T1 TFE, TR/TE=8.4/3.9 ms, flip angles=8°, 
bandwidth=191 Hz/pixel, 220 slices, voxel size 1 mm3 isotropic, acquisition matrix: 240 × 
240 mm, SENSE factor 2.5) were acquired for anatomical reference. Two fast field echo 
images (T1 FFE, TR/TE=8.4/3.7 ms, flip angles=3° and 17°, band width=191 Hz/pixel, 160 
slices, voxel size 1 mm3 isotropic, acquisition matrix: 256 × 256 mm, SENSE factor 2) were 
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used to estimate R1 in the ROIs. T1 values were calculated by the variable flip angle method 
(Sabati and Maudsley, 2013). T1 maps were corrected for field inhomogeneity by dual-TR 
B1 maps. Five 3D fast field echo images with different echo times (FFE, TR/TE/
delta_TE=24.3/3.7/4.4 ms, flip angle=20°, bandwidth=287 Hz/pixel, 80 slices, voxel size 
(1.5 mm)3 isotropic, acquisition matrix: 256 × 256 mm, SENSE factor 2) were acquired to 
estimate R2* in the ROIs. T2* values were calculated by fitting the signal intensity as a 
function of echo time using the exponential decay model (Long et al., 2014a).
Additionally, fast T2-weighted images (TR/TE = 6000/127 ms) in all three planes were 
acquired for planning the 30 mm × 30 mm × 25 mm MRS VOIs centered on the thalamus 
and on the striatum (head of caudate nucleus, putamen and part of GP interna) of both 
hemispheres. Brain tissue segmentation into gray matter (GM), white matter (WM), and 
cerebrospinal fluid (CSF) was based on superimposing the spectroscopy VOI coordinates on 
high resolution T1-weighted image using the partial volume correction tool by Nia Goulden 
and Paul Mullins (https://www.bangor.ac.uk/psychology/biu/Wiki.php.en) with the SPM 
Tool Segmentation (SPM8) as formerly described (Ashburner and Friston, 2005).
Both, short echo time point resolved spectroscopy (PRESS) spectra (echo time (TE) = 30 
ms, repetition time (TR) = 2000 ms, 32 averages) and MEGA-PRESS edited GABA spectra 
(TE/TR = 68/2000 ms, edit ON acquisitions=16, edit OFF acquisitions=16) were acquired 
from each VOI. In conventional MRS the GABA peak is overlaid by the much larger tCr 
peak. Therefore, the special GABA-editing MRS technique MEGA-PRESS is used, allowing 
for a better detection of the small GABA signal (Mullins et al., 2014). In addition, reference 
spectra without water suppression were obtained for phase, frequency and eddy current 
correction.
Post-processing and quantification of GABA spectra were done in LCModel (v 6.2-0R), a 
spectral quantification tool that fits each spectrum as a weighted linear combination of basis 
spectra from individual brain metabolites (Provencher, 1993). The basis set included Glu, 
Gln, tCr, glycerophosphocholine (GPC), phosphocholine (PCh), NAA, NAAG, mI, and 
several minor metabolites. Furthermore, three metabolite sums were examined: Glx = Glu + 
Gln, total choline (Cho) = GPC + Ph, and total NAA = NAA + NAAG. All neurometabolite 
concentrations were scaled with respect to the unsuppressed water signal. Tissue correction 
of neurometabolite content is commonly applied to correct the acquired MRS data for the 
segmentation of VOIs, assuming no metabolic activity in CSF. For descriptive analyses CSF-
corrected concentrations [mM] were presented (Chowdhury et al., 2015). However, for the 
regression models water-scaled metabolite values in institutional units [i.u.] were used and 
CSF content was included in the regression models together with other covariates such as 
age or smoking in addition to exposure measures.
LCModel also provides an estimated relative standard deviation (%SD) for each metabolite 
as a measure of the believability of the concentration values reported. Only results with 
%SD values < 20% were used for further statistical analysis.
An example of the MRS VOIs and MRI ROIs is shown in Figure 1.
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Statistics—All calculations were done using SAS, version 9.4 (SAS Institute Inc., Cary, 
NC, USA). Continuous variables were described with median and inter-quartile range (IQR). 
For descriptive purposes, we presented the arithmetic mean from the left and right 
hemisphere of GABA and each other neurometabolite. The distribution of the exposure 
variables in welders were stratified by welding technique (GMAW vs. other technique). 
Rank correlations between variables were presented by Spearman’s correlation coefficient 
(rS) with 95% confidence interval (CI). In addition, partial Spearman correlation coefficients 
(rSp) with 95% CIs were used to describe the associations between neurometabolites, while 
controlling for CSF content in the VOIs. Linear mixed models were applied to the log-
transformed striatal and thalamic neurometoblite concentrations to estimate the influence of 
exposure to Mn and Fe while controlling for other covariates. The study group and the 
exposure variables were fixed factors. We chose subject as random factor to consider the 
dependence of the four measurements in both brain regions (striatum, thalamus) and 
hemisphere (left, right) per subject. Additionally, linear mixed models were applied in active 
welders to investigate the association of neurometabolites with airborne Mn and Fe. All 
models were adjusted for age, smoking status (never, former, current), CDT (≤ 2.6%, > 
2.6%), and CSF content [%].
3. Results
3.1 Demographics and covariates of the exposure to Mn and Fe
Table 1 depicts the distribution of socio-demographic characteristics and biomarkers of 
exposure to Mn and Fe (blood: MnB, SF, SFe; brain: R1, R2* in ROIs) in 154 participants of 
WELDOX II. The median age of all men was 56 years (IQR 50–64). Active and former 
welders worked long-term in this occupational setting (median 27 years (IQR 24–33) and 33 
years (IQR 27–43), respectively). On average, former welders were not exposed to welding 
fumes for seven years. The fractions of blue-collar jobs as longest held occupation were 
100% in all welders, 41% in controls, 53% in PD, and 25% in HC. More welders smoked at 
some point in their lives and had a lower education than the other study groups. GGT above 
the reference value of 56 U/L was observed in 19% of active and in 35% of the former 
welders, in 15% of controls and in 17% of patients with PD, but in none of the HC patients. 
Six out of eight men with CDT > 2.6% were welders, but we observed none of the patients 
with PD or HC with elevated CDT.
Median MnB ranged from 7.6 μg/L (IQR 6.7–9.3) in active welders to 6.2 μg/L (IQR 5.6–
8.5) in HC patients. Median SF was highest in former welders (241.5 μg/L, IQR 111–434) 
and lowest in HC (44 μg/L, 29.5–186). A similar pattern was shown for transferrin. On the 
other hand, we observed an opposite pattern for SFe (former welders: 93.5 μg/dL, PD: 95 
μg/dL, HC: 121.5 μg/dL). Active welders had similar median concentrations of SFe as 
controls (103 μg/dL and 105 μg/dL), but a higher median of SF (131 μg/L and 74 μg/L, 
respectively). The medians of R1 in GP ROIs reflect partially the ranking of MnB being 
highest in active welders and lowest in HC. The medians of the corresponding R2* values 
were also lowest in HC but highest in PD.
The median exposure to respirable Mn and Fe in active welders was 23 μg/m3 (IQR 4.7–86) 
and 110 μg/m3 (IQR 14–400), respectively. GMAW was used by 21 active (45%) and 13 
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former welders (65%). Median shift exposure to respirable Mn and Fe were higher when 
using GMAW (Mn: 57 (IQR 33–130) μg/m3, Fe: 360 (IQR 190–750) μg/m3) than TIG and 
other techniques (Mn: 5 (IQR 2–23) μg/m3, Fe: 15 (IQR 5–84) μg/m3). In active, but not in 
former welders, MnB and SF were higher when using GMAW. The neurometabolite 
concentrations did not differ between welding techniques. For more details see 
Supplemental Table S1.
3.2 Distribution of neurometabolites in the striatum and thalamus
We measured neurometabolites in both hemispheres. Concentrations in the right and left 
hemispheres were correlated, especially in the thalamus (data not shown). However, striatal 
GABA, Glu and Glx did not correlate between the two hemispheres.
Table 2 depicts the distribution of different brain tissue contributions in the voxels and the 
content of neurometabolites as arithmetic mean of both hemispheres in the VOIs placed in 
striatum and thalamus. As expected, the tissue content of the striatum voxels differed from 
that in the thalamus (e.g. GMStr 32.5% vs. GMThal 20.9%, WMStr 55% vs. WMThal 70.7%) 
with minor differences between the study groups. In general, the CSF content was low 
(CSFStr 12.0%, CSFThal 8.3%). As shown in Supplemental Table S2, the neurometabolite 
concentrations correlated negatively with the CSF content of the VOIs and frequently 
positively with the GM and WM content
The GABA concentration was 2.0 mM in the striatal and thalamic VOIs and did not differ 
between the study groups. The concentrations of other neurometabolites varied slightly 
between brain regions and groups as shown in Table 2. Glx and tCr were higher in the 
striatum but NAA was lower as compared with the VOIs in the thalamus. Striatal tCr was 
highest in controls. Supplemental Table S2 also shows significant correlations of the 
respective neurometabolites measured in striatum vs. thalamus adjusted for the CSF content. 
Thalamic GABA was not correlated with other neurometabolites in this brain region 
whereas Glx, NAA and tCr showed significant associations (Glx and tCr rSp = 0.32). By 
contrast, striatal GABA was correlated with Glx and tCr and showed marginal positive 
associations with the other metabolites.
Supplemental Table S3 presents the correlations of neurometabolites adjusted for the CSF 
content with age, biomarkers for Mn and Fe in blood and brain in all participants and for 
airborne Mn and Fe in active welders only. We observed no clear pattern of the associations 
between the other neurometabolites and exposure to Mn or Fe in air, blood or assessed with 
the surrogate markers R1 and R2* for metal accumulation in the GP. The associations 
observed in the striatum were mostly weaker than in the thalamus. These correlations were 
not adjusted for covariates or multiple tests. We account for the complex influences of 
neuroanatomy, age and exposure in the statistical models presented in Table 3.
3.3 Potential predictors of neurometabolites
The effect estimates for the various exposure measures and potential confounders of the 
neurometabolites assessed with mixed linear regression models using MRS measurements of 
both assessed brain regions and hemispheres of the participants are shown in Table 3. The 
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level-two variance estimates reflect the correlations between the neurometabolite 
concentrations of the four VOIs.
In all models, we adjusted the potential influence of exposure to Mn or Fe for smoking, 
CDT, age, and %CSF. In addition, we included the results in both brain regions and 
hemispheres. As expected, a higher CSF content and higher attained age resulted in 
decreased neurometabolite concentrations. Concentrations of GABA, NAA, total NAA, and 
mI were lower in the striatum than in the thalamus and vice versa for Glu, Glx, and tCr. 
Smoking status played a subordinate role with smokers having lower GABA concentrations 
than never smokers, and former smokers having higher concentrations in all other 
neurometabolites than never smokers. CDT > 2.6% was associated with lower 
concentrations of most neurometabolites, especially in total NAA with exp(β)=0.95 
(p=0.04).
We successively implemented the five different exposure variables in the various models. We 
observed no influence of any exposure measure on GABA. In model 1, being a welder or a 
patient with PD or HC was compared to controls. tCr was lower in these study groups than 
in controls. The effects of systemic exposure (MnB and iron status) on neurometabolite 
concentrations are investigated in model 2. Whereas MnB was only marginally associated 
with total NAA (p=0.07), SF and SFe influenced NAA and total NAA in opposite directions. 
In model 3, higher R1 values resulted in lower neurometabolite concentrations with 
significant outcomes for tCr (exp(β)=0.87, p=0.005) and Cho (exp(β)=0.84, p=0.04) and 
marginally for Glu and NAA. Higher R2* values resulted in higher concentrations of Glx 
and lower concentrations of mI. R1 and R2* in the SN and FL did not affect neurometabolite 
concentrations (data not shown). Respirable Mn and Fe did not influence the 
neurometabolite content among active welders (models 4 and 5).
4. Discussion
This study employs a non-invasive MRI/MRS technique to quantify the concentrations of 
GABA and other neurometabolites in the striatum and thalamus of welders exposed to 
airborne Mn and Fe in an occupational environment, along with several other study groups. 
Differences in metal exposure were assessed by study group, systemic biomarkers (MnB, SF 
and SFe), metal accumulation in brain regions of interest (R1, R2*), as well as airborne 
exposure to Mn and Fe in active welders only. Based on the data acquired, we observed that 
MRI measures of metal accumulation rather than biomarkers of systemic exposures to 
metals were associated with the neurometabolite concentrations in the VOIs under study. 
Airborne exposure was not associated with neurometabolite concentrations.
An advantage of this neuroimaging study is its large size facing the efforts to recruit and 
investigate men on a voluntary basis for MRI/MRS. Notably, neuroimaging was conducted 
with a median time lag of six weeks regarding the shift measurements in active welders. 
This and the relatively low airborne exposure among active welders with median respirable 
Mn of 23 μg/m3, which is in the range of the German OEL of 20 μg/m3, may explain the 
rather similar GABA concentrations among the different study groups. By contrast to a 
report of increased GABA in a small group of Chinese smelters in a thalamus/basal ganglia 
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VOI (Dydak et al., 2011), we did not find any statistically significant differences between 
welders and other study groups. Methodological challenges arise due to the low GABA 
concentration and overlapping spectra (Aufhaus et al., 2013; Mullins et al., 2014) resulting 
in a larger variability and lower sensitivity to measure GABA. Furthermore, the manual 
placing of VOIs and ROIs is subject to the expertise of the observer, which we controlled by 
independent raters.
The neurometabolite concentrations within the various VOIs were strongly correlated. This 
may indicate a VOI-specific metabolome, beyond the macroscopic neuroanatomical 
structures GM, WM and CSF. This correlation is weaker with GABA, which may be due to 
the larger variability and lower sensitivity to measure GABA. Glu is a major transmitter for 
excitatory neurons and precursor of GABA, which is the major inhibitory neurotransmitter 
in the adult brain (Bak et al., 2006; Beleboni et al., 2004). The Gln/Glu-GABA cycle reflects 
interactions between astrocytes and neurons, as only astrocytes synthesize Gln (Aschner et 
al., 1992). Here, we observed significant correlations between GABA, Glu, and Glx in the 
striatum, but not in the thalamus. Mn accumulation in astrocytes has been associated with 
the disruption of striatal Gln/Glu-GABA cycle (Bak et al., 2006). This may be reflected in 
lower concentrations of GABA, Glu, and Gln in specific brain regions, which may explain 
the observed correlation, although the results from other studies are inconsistent (Sidoryk-
Wegrzynowicz and Aschner, 2013).
Also MnB and SF as measures of systemic exposure to Mn and Fe were not associated with 
GABA and Glx. We further used R1 as exposure metric for brain metal accumulation and 
found a weak association of R1 in ROIs of the GP with lower levels of both 
neurometabolites in the striatum and thalamus. This effect remained rather stable in all 
models, but did not reach statistical significance. Furthermore, R2* in GP influenced Glx in 
the VOIs in an opposite direction. R2* is commonly used to assess brain iron content 
(Fitsanakis et al., 2006). Abnormal accumulation of brain iron has been detected in various 
neurodegenerative diseases (Rouault, 2013), but the contribution of iron overload to the 
brain metabolism remains unclear.
The energy demand of the brain is especially high, where iron plays a major role (Ward et 
al., 2014). Creatine is a regulator of energy homeostasis in the brain and influences 
GABAergic and glutamatergic neurotransmission, among other functions (Joncquel-
Chevalier Curt et al., 2015). Its concentration in GM is higher than in WM, reflecting higher 
ATP metabolism (Hetherington et al., 2001). Lower concentrations of creatine were 
observed in the basal ganglia (Mak et al., 2009). Creatine had been found stable and was 
used as internal reference for the voxel content of GABA when estimating Mn or other 
effects (Chang et al., 2009; Dydak et al., 2011). However, in our data tCr was lower in 
welders and PD or HC patients than in controls, and we observed a negative association with 
R1 in GP. Therefore, tCr is likely not a “neutral” neurometabolite to adjust effects of redox-
active metals on GABA. Of note, creatine synthesis usually occurs in kidney and liver where 
the metabolism is subject to influences of ingestion, aging and other factors (Joncquel-
Chevalier Curt et al., 2015). This would implicate a wider range of potential covariates when 
exploring the tCr content of the brain.
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As GABA concentrations are highest in GM, precise tissue segmentation is important 
(Harris et al., 2015). Also microstructural changes, for example of the Fe content and 
myelination, might influence the GABA determination (Lorio et al., 2014). Besides 
neurotoxic or neurodegenerative effects of Mn and Fe on GM, also a methodological 
problem should be considered. Both metals correlate with MRI parameters such as R1 or 
R2* and can thus influence the GM-WM contrast (Lorio et al., 2014; Zhang et al., 2009). 
Alternative segmentation procedures should be tested when studying metal effects.
5. Conclusions
Our data does not show an association of any measure of exposure with the MRS-derived 
GABA concentration. However, the exposure levels of our welders were low. Our results do 
not provide evidence that striatal or thalamic GABA was different in Mn-exposed workers or 
patients with PD or HC as compared to controls. However, tCr was lower in these study 
groups than in controls. We further showed that the content of all neurometabolites in the 
VOIs was lower with higher R1 indicating an influence of the metal accumulation in brain 
regions of interest.
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Highlights
• This neuroimaging study examines striatal and thalamic neurometabolites of 
154 men.
• MRI measures of metal accumulation were associated with neurometabolite 
levels.
• Total creatine was lower in welders than in controls.
• Serum ferritin and iron were only associated with N-acetylaspartate.
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Figure 1. 
Representative T1-weighted MRI brain images of an active welder with MRS voxels in the 
thalamus and striatum, and ROIs in the substantia nigra, globus pallidus and frontal lobe
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